Strong EGFR Signaling in Cell Line Models of ERBB2-amplified Breast Cancer Attenuates Response Towards ERBB2-targeting Drugs

Oncogenesis - United States
doi 10.1038/oncsis.2012.16
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

AKT Signaling in ERBB2-amplified Breast Cancer

Pharmacology and Therapeutics
Pharmacology
2016English

Novel Peptide/Protein Delivery System Targeting erbB2-Overexpressing Breast Cancer Cells

2000English

Novel Peptide/Protein Delivery System Targeting erbB2-Overexpressing Breast Cancer Cells

2002English

Conditional Knockout of SHP2 in ErbB2 Transgenic Mice or Inhibition in HER2-amplified Breast Cancer Cell Lines Blocks Oncogene Expression and Tumorigenesis

Oncogene
Cancer ResearchGeneticsMolecular Biology
2018English

ErbB2 Regulation of C-SRC Activity in Breast Cancer

2000English

Role of Integrin Alpha 5 in ErbB2-Mediated Breast Cancer

2009English

An Insertion Mutation of ERBB2 Enhances Breast Cancer Cell Growth and Confers Resistance to Lapatinib Through AKT Signaling Pathway

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2020English

Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Preexisting Oncogenic Events Impact Trastuzumab Sensitivity in ERBB2-amplified Gastroesophageal Adenocarcinoma

Journal of Clinical Investigation
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy